Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?

European Psychiatry

Volumn 18, Issue 2, 2003, Pages 82-84

  Godemann, F ^a   Linden, M ^b   Gaebel, W ^c   Kopke W ^d   Muller P ^e   Muller Spahn F ^f   Tegeler, J ^g   Pietzcker, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Rehabilitationsklinik Seehof   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d Klin Poliklin Psychiat Psychoter   (Germany)

^e Klin fur Psychiat Psychotherapie   (Germany)

^f UNIVERSITY OF BASEL   (Switzerland)

^g Klinik und Poliklinik fur Psychiatrie   (Germany)

Author keywords

Compliance; Interval; Long term medication; Neuroleptic drugs; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CHRONICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOPERATION; DEFENSE MECHANISM; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0038304127     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(03)00008-7     Document Type: Article

References (10)

1. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-48.
2. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73.
3. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al. Intermittent vs. maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991;48:333-9.
4. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry 1988;45:797-805.
5. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996;312:345-9.
6. Linden M, Godemann F, Gaebel W, Köpke W, Müller P, MüllerSpahn F, et al. A prospective study of factors influencing adherence to continuous neuroleptic treatment in schizophrenic patients during 2 years. Schizophr Bull 2001;27:585-96.
7. Linden M, Nather J, Wilms HU. Definition, significance and measurement of disease concepts of patients. The disease concept scale for schizophrenic patients. Article in German. Fortschr Neurol Psychiatry 1988;56:35-43.
8. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl):133-8.
9. Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, MüllerSpahn F. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia-2-year results of a german multicenter study. J Psychiatry Res 1993,27:321-39.
10. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-82.